The updated landscape of tumor microenvironment and drug repurposing

MZ Jin, WL Jin - Signal transduction and targeted therapy, 2020 - nature.com
Accumulating evidence shows that cellular and acellular components in tumor
microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and …

Prostaglandin E2 and cancer: insight into tumor progression and immunity

F Finetti, C Travelli, J Ercoli, G Colombo, E Buoso… - Biology, 2020 - mdpi.com
Simple Summary Inflammation is assessed as a hallmark of cancer and it is now widely
recognized that there exists a direct causal link between inflammation and tumors. Among …

[HTML][HTML] Eicosanoids in cancer: new roles in immunoregulation

AM Johnson, EK Kleczko, RA Nemenoff - Frontiers in pharmacology, 2020 - frontiersin.org
Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily
through the action of cytosolic phospholipase A2-α. Three major downstream pathways …

Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases

D Panigrahy, A Gartung, J Yang… - The Journal of …, 2019 - Am Soc Clin Investig
Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an
inflammatory/immunosuppressive injury response that promotes dormancy escape and …

[HTML][HTML] Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer

D Pu, L Yin, L Huang, C Qin, Y Zhou, Q Wu, Y Li… - Frontiers in …, 2021 - frontiersin.org
The clinical application of immunotherapy is the milestone of cancer treatment. However,
some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in …

Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?

G O'callaghan, A Houston - British journal of pharmacology, 2015 - Wiley Online Library
Elevated expression of COX‐2 and increased levels of PGE2 are found in numerous
cancers and are associated with tumour development and progression. Although …

Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer

DJ Stewart - Critical reviews in oncology/hematology, 2010 - Elsevier
While chemotherapy provides useful palliation, advanced lung cancer remains incurable
since those tumors that are initially sensitive to therapy rapidly develop acquired resistance …

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors

AJ Muller, PA Scherle - Nature Reviews Cancer, 2006 - nature.com
Cancer immunotherapy has been predominantly focused on biologically based intervention
strategies. However, recent advances in the understanding of tumour–host interactions at …

Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions

X Tang, D Liu, S Shishodia, N Ozburn… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Nuclear factor‐κB (NF‐κB), a key transcription factor thought to play a
major role in carcinogenesis, regulates many important signaling pathways involved in …

Improving cancer immunotherapy by targeting tumor-induced immune suppression

TJ Stewart, MJ Smyth - Cancer and Metastasis Reviews, 2011 - Springer
The status of a host's immune response influences both the development and progression of
a malignancy such that immune responses can have both pro-and anti-tumorigenic effects …